|
Press Releases |
|
|
|
Friday, December 18, 2020 |
|
Hua Medicine Completes Registration Phase III Trials; Announces 52-Week Result for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial |
Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced: more info >> |
|
Wednesday, October 14, 2020 |
|
Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin |
Hua Medicine (the "Company", Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder ("MAH") system, the Company has obtained the drug manufacturing permit for dorzagliatin, its investigational first-in-class drug, issued by the Shanghai Municipal Drug Administrative Bureau. more info >> |
|
Monday, August 17, 2020 |
|
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China |
Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. more info >> |
|
Wednesday, July 1, 2020 |
|
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin |
Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes. more info >> |
|
Thursday, June 18, 2020 |
|
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial |
Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301) more info >> |
|
Monday, April 27, 2020 |
|
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor) |
Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. more info >> |
|
Monday, March 16, 2020 |
|
Hua Medicine Announces 2019 Annual Results |
Hua Medicine (the "Company", Stock Code on The Stock Exchange of Hong Kong Limited: 2552.HK), a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, today announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019. more info >> |
|
Friday, February 14, 2020 |
|
Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer |
Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, is pleased to announce that Dr. Fuxing Tang has joined Hua Medicine as Chief Technology Officer, VP of Formulation R&D and Product Development. more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
UK advertising reports GBP36.6bn spend in 2023
Apr 26, 2024 17:30 HKT/SGT
|
|
|
CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine
Apr 26, 2024 15:36 HKT/SGT
|
|
|
Edvantage Group Announces FY2024 Interim Results
Apr 26, 2024 13:43 HKT/SGT
|
|
|
Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project
Apr 26, 2024 13:27 HKT/SGT
|
|
|
Imexpharm Corporation Hosts Shareholders, Analysts and Potential Investors at its 2024 Annual General Meeting
Apr 26, 2024 13:16 HKT/SGT
|
|
|
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
|
|
|
Jeff Martin Auctioneers to Manage Sale of Sabine Mining Company Assets for North American Coal
Apr 26, 2024 08:00 HKT/SGT
|
|
|
Cambridge Isotope Laboratories (CIL) Shows Long-Term Commitment to Xenia, Ohio, Facility With New Land Purchase
Apr 25, 2024 21:00 HKT/SGT
|
|
|
Black Spade Donates Art and Jewellery Collection To Hong Kong Red Cross
Apr 25, 2024 20:40 HKT/SGT
|
|
|
Q2 Metals Announces Assay Results from Its 2023 Inaugural Drill Program at the Mia Lithium Property, James Bay Territory, Quebec, Canada
Apr 25, 2024 19:09 HKT/SGT
|
|
|
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
|
|
|
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
|
|
|
8 in 10 Singapore businesses experienced more change in last 4 years than previous two decades: HubSpot Research
Apr 25, 2024 16:00 HKT/SGT
|
|
|
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
|
|
|
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|